Table 2.

Gender stratified marginal single nucleotide polypmorphism (SNP) results for abstinence rates

SNP	Gene Region	Chromosome	Male				Female
			MAF	SNP OR (95% CT)	Observed P	Adjusted Pa	MAF	SNP OR (95% CI)	Observed P	Adjusted Pa
Significant SNPs within Males
End of treatment
rs6702335b	EPB41	1	0.39	0.46 (0.32–0.64)	2.30 × 10−6	3.27 × 10−5	0.39	0.93 (0.67–1.30)	6.67 × 10−1	1
rs12021667b	EPB41	1	0.4	0.45 (0.32–0.64)	2.01 × 10−6	3.65 × 10−5	0.39	0.96 (0.69–1.34)	8.15 × 10−1	1
rs12027267b	EPB41	1	0.4	0.46 (0.33–0.64)	2.38 × 10−6	4.04 × 10−5	0.39	0.95 (0.68–1.33)	7.62 × 10−1	1
rs12039988b	EPB41	1	0.39	0.47 (0.33–0.65)	3.40 × 10−6	5.77 × 10−5	0.39	1.00 (0.72–1.40)	9.97 × 10−1	9.97 × 10−1
rs203278b	EPB41	1	0.35	2.27 (1.44–3.60)	3.30 × 10−4	5.57 × 10−3	0.34	0.79 (0.50–1.25)	3.20 × 10−1	9.74 × 10−1
rs150089	EPB41	1	0.32	1.71 (1.23–2.39)	1.48 × 10−3	2.20 × 10−2	0.31	0.86 (0.61–1.23)	4.09 × 10−1	9.91 × 10−1
rs2985322	EPB41	1	0.32	1.71 (1.23–2.39)	1.48 × 10−3	2.22 × 10−2	0.31	0.87 (0.61–1.24)	4.38 × 10−1	9.94 × 10−1
rs578776	CHRNA3;CHRNA5	15	0.24	1.75 (1.21–2.54)	2.86 × 10−3	2.85 × 10−2	0.21	0.94 (0.63–1.39)	7.47 × 10−1	9.99 × 10−1
rs4654390	EPB41	1	0.5	0.62 (0.45–0.85)	2.48 × 10−3	3.50 × 10−2	0.49	0.98 (0.72–1.34)	8.97 × 10−1	1
rs10915216	EPB41	1	0.5	0.62 (0.45–0.85)	2.68 × 10−3	3.72 × 10−2	0.49	0.97 (0.71–1.33)	8.70 × 10−1	1
6-month Follow-up
rs6702335b	EPB41	1	0.39	0.46 (0.31–0.67)	3.44 × 10−5	6.97 × 10−4	0.39	1.11 (0.77–1.59)	5.87 × 10−1	1
rs12027267b	EPB41	1	0.4	0.46 (0.31–0.68)	3.89 × 10−5	7.95 × 10−4	0.39	1.17 (0.81–1.69)	3.97 × 10−1	9.91 × 10−1
rs12021667b	EPB41	1	0.4	0.48 (0.32–0.70)	8.25 × 10−5	1.61 × 10−3	0.39	1.16 (0.80–1.66)	4.37 × 10−1	9.96 × 10−1
rs12039988b	EPB41	1	0.39	0.40 (0.24–0.66)	2.89 × 10−4	5.26 × 10−3	0.39	1.53 (0.89–2.63)	1.20 × 10−1	7.83 × 10−1
rs2238687	FOSB	19	0.14	2.17 (1.33–3.55)	2.42 × 10−3	1.48 × 10−2	0.14	1.57 (0.99–2.49)	6.30 × 10−2	2.62 × 10−1
rs11101694	CALY	10	0.13	0.42 (0.21–0.85)	1.01 × 10−2	3.74 × 10−2	0.12	0.84 (0.44–1.59)	5.89 × 10−1	5.89 × 10−1
rs16837840	EPB41	1	0.11	2.40 (1.38–4.17)	2.46 × 10−3	3.78 × 10−2	0.1	0.70 (0.35–1.41)	3.01 × 10−1	9.71 × 10−1
Significant SNPs within Females
End of treatment
rs4809549	CHRNA4	20	0.47	1.00 (0.74–1.35)	9.96 × 10−1	9.96 × 10−1	0.48	0.59 (0.42–0.83)	1.99 × 10−3	1.69 × 10−2
rs7123797	ANKK1	11	0.34	0.95 (0.62–1.46)	8.23 × 10−1	1	0.34	0.46 (0.29–0.73)	8.58 × 10−4	1.86 ×10−2
rs4938012	ANKK1	11	0.33	0.97 (0.63–1.48)	8.74 × 10−1	1	0.33	0.47 (0.29–0.74)	1.09 × 10−3	2.33 × 10−2
rs17115439	ANKK1	11	0.33	0.94 (0.61–1.44)	7.67 × 10−1	1	0.33	0.47 (0.30–0.75)	1.45 × 10−3	3.02 × 10−2
rs4938015	ANKK1	11	0.33	0.94 (0.61–1.44)	7.67 × 10−1	1	0.33	0.47 (0.30–0.75)	1.49 × 10−3	3.10 × 10−2
6-month Follow-up
rs3766927	CHRNB2	1	0.31	0.86 (0.53–1.39)	5.30 × 10−1	7.77 × 10−1	0.29	0.45 (0.26–0.76)	2.24 × 10−3	1.92 × 10−2
rs1127314	CIIRNB2	1	0.31	0.88 (0.62–1.27)	4.99 × 10−1	7.99 × 10−1	0.29	0.53 (0.34–0.82)	2.48 × 10−3	2.07 × 10−2
rs2834600	CLIC6	21	0.13	0.89 (0.51–1.57)	6.93 × 10−1	9.87 × 10−1	0.14	2.29 (1.34–3.91)	2.86 × 10−3	3.08 × 10−2
rs17759598	MAPK1	22	0.17	0.87 (0.55–1.39)	5.67 × 10−1	9.82 × 10−1	0.14	0.44 (0.23–0.83)	5.60 × 10−3	3.71 × 10−2
rs2131902	CHRMB2	1	0.32	0.82 (0.50–1.33)	4.20 × 10−1	8.24 × 10−1	0.3	0.49 (0.29–0.82)	5.66 × 10−3	4.33 × 10−2

All models were adjusted for age, FTND, and treatment.

SNPs above the dashed line have adjusted P-values < 0.05 within males. SNPs below the dashed line have adjusted P-values < 0.05 within females.

^aP-values adjusted for the number of correlated tests within respective gene regions.

^bAdjusted SNP × Gender Interaction P-value < 0.05.